By Josh White
Date: Monday 14 Nov 2016
LONDON (ShareCast) - (ShareCast News) - Hutchison China MediTech presented data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokinetics and pharmacodynamics of single and multiple doses of HMPL-523 on Monday, to the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, being held in Washington DC.
The AIM-traded firm's presentation included additional data on HMPL-523, a highly selective, potent and orally available inhibitor of Spleen Tyrosine Kinase (Syk).
It said Syk plays a pivotal role in the regulation of downstream signaling in immune receptors, including B cell receptors, which play a key role in autoimmune diseases such as rheumatoid arthritis.
The Phase I dose-escalating study to assess safety, tolerability and PK of HMPL-523 was completed in healthy volunteers in Australia in late 2015.
"HMPL-523 was administered at up to 800mg as a single dose and up to 400mg in multiple doses in 14 cohorts," the board said.
"The treatment was generally well tolerated without material off-target toxicities, including lower rates of diarrhea and hypertension compared to what had been observed in first-generation Syk inhibitors.
"Furthermore, HMPL-523 demonstrated a dose-dependent suppression of B-cell activation. The Company plans to initiate a Phase II study in the US in 2017."
HMPL-523 is also being studied in oncology indications, Chi-Med reported.
"A Phase I dose escalation study was initiated in Australia in January 2016 and is expected to complete in the first half of 2017.
"This study is in patients with relapsed and/or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia for whom there is no standard therapy."
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 323.00p |
Change Today | -1.00p |
% Change | -0.31 % |
52 Week High | 352.00 |
52 Week Low | 173.60 |
Volume | 2,416 |
Shares Issued | 871.26m |
Market Cap | £2,814.16m |
RiskGrade | 226 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
10:05 | 1,562 @ 320.12p |
10:04 | 1 @ 320.01p |
09:44 | 157 @ 320.40p |
09:02 | 96 @ 323.00p |
08:57 | 154 @ 321.95p |
You are here: research